Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 688-kidney-and-urinary-tract-neoplasms-without-cc-mcc
    Ask Trek AI about this page

    Kidney and Urinary Tract Neoplasms without CC/MCC: Inpatient Reimbursement Overview

    DRG 688 encompasses kidney and urinary tract neoplasms without Complication or Comorbidity or Major Complication or Comorbidity, covering lower-complexity inpatient stays where primary tumor management is performed without significant comorbid burden. Precise coding drives Diagnosis-Related Group assignment and therefore materially affects Medicare inpatient reimbursement and hospital financial planning.

    Customize your policy alerts

    Sign up for drg 688 policy alerts

    Get alerted when payer policies referencing 688 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 688 Overview

    DRG 688 covers inpatient stays for kidney and urinary tract neoplasms without Complication or Comorbidity or Major Complication or Comorbidity, typically including straightforward surgical resections, ablations, or diagnostic admissions for localized tumors. This Diagnosis-Related Group groups claims with lower expected resource use than cases with complications, which affects relative payment weight under Medicare inpatient prospective payment. Accurate coding of principal diagnosis and comorbid conditions determines assignment to this Diagnosis-Related Group and therefore influences reimbursement. The classification is important for hospital case-mix, payment forecasting, and compliance with Centers for Medicare & Medicaid Services billing rules.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative management and surgical technique trials testing minimally invasive nephrectomy approaches versus open surgery for localized kidney tumors, focusing on intraoperative outcomes, perioperative complication rates, and short-term recovery metrics. These studies enroll adult inpatients with renal or upper urinary tract neoplasms who are candidates for partial or radical nephrectomy and seek to define which surgical approach reduces blood loss, length of stay, and postoperative complications. This research is directly relevant to providers and payers because differences in operative morbidity and hospitalization duration drive inpatient resource use, DRG reimbursement optimization, and downstream costs related to complications.
    • Comparative effectiveness studies evaluating adjuvant and neoadjuvant systemic or localized therapies in patients with high-risk resectable tumors, assessing recurrence-free survival, impact on need for additional inpatient care, and toxicity profiles that may require hospitalization. These trials include patients with pathologic features or clinical staging that confer higher risk of recurrence, and they aim to determine whether perioperative therapy reduces recurrence and subsequent inpatient utilization versus surgery alone. Payers and hospital administrators prioritize this evidence to balance drug toxicity that could increase inpatient stays against potential reductions in future admissions from metastatic progression.
    • Post-discharge outcomes and care coordination research examining readmission rates, renal function preservation, and quality-of-life trajectories after hospitalization for nephrectomy or tumor-directed procedures, often testing interventions such as enhanced recovery pathways, structured follow-up, or remote monitoring. Study populations include medically complex inpatients (older adults, CKD comorbidity, or multiple prior admissions) who are at higher risk for readmission or decline in kidney function, with the goal of reducing preventable rebound hospital use. Insights from these studies help providers implement protocols that lower avoidable readmissions and help payers forecast post-acute costs associated with this DRG.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.